Promente Sp. z o.o. — Clinical Trial Site

12 Registered trials

2 Currently recruiting

Organisation

Promente Sp. z o.o.

Location

Bydgoszcz, Poland

Identifier

ORG-100044491

Address

Ul. Teofila Lenartowicza 33/35, 85-133, Poland

Departments

#40606:Promente-Centrum Neurologii i Psychogeriatrii
Centrum Neurologii i Psychogeriatrii w Bydgoszczy
N/A
NA
Not applicable
PROMENTE - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
Promente -Centrum Neurologii i Psychogeriatrii w Bydgoszczy-this is medical entity where is trial
Promente Sp. z o.o.- Centrum Neurologii i Psychogeriatrii
Psychiatry

Clinical trials at this site (12)

Search interface

A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised

2022-501644-15-00 Mild Cognitive Impairment due to Alzheimer's Disease Al 4
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Pending

2024-516805-22-00 Major Depressive Disorder 5
A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder Recruiting

2024-519270-40-00 Major Depressive Disorder 5 2025-10-30
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Major Depressive Disorder with Insomnia Symptoms 5 2025-03-18
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder Ended

2023-505892-56-00 Major Depressive Disorder 5 2024-09-30
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit… Ended

2023-506335-15-00 Major Depressive Disorder 5 2024-07-18
A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended

2023-505268-12-00 Treatment-resistant depression 5 2024-02-09
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 4 2023-09-28
A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early… Halted

2024-518523-30-00 early Alzheimer’s disease 4 2023-11-08
Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102 Ended

2023-503729-20-00 Alzheimer’s Disease 3 2024-03-27
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended

2023-506170-12-00 Alzheimer’s Disease 4 2021-10-18